Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Tonix Pharma ( (TNXP) ) has issued an announcement.
On February 6, 2025, Tonix Pharmaceuticals announced encouraging Phase 1 trial results for its TNX-1500 product, a next-generation anti-CD40L monoclonal antibody, in healthy participants. The trial demonstrated that TNX-1500 was well-tolerated and effective in modulating immune responses, showing potential as a superior option in preventing organ transplant rejection with reduced toxicity compared to existing immunosuppressive treatments.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates within the pharmaceutical industry, focusing on innovative therapies. Its primary product offerings include monoclonal antibodies, with current developments aimed at improving transplant outcomes.
YTD Price Performance: -54.58%
Average Trading Volume: 1,405,056
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $83.74M
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.
